Is Concord Biotech Ltd debt-free?

Yes, Concord Biotech Ltd is debt-free with a debt-to-equity ratio of 0.00.

Home

Concord Biotech Ltd

Concord Biotech Ltd Financials

Concord Biotech Ltd Financial Statement

Concord Biotech Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Mar 2025	Dec 2024	Sep 2024
Revenue	439.27	258.95	320.21
Operating Expense	239.46	146.27	173.50
Net Profit	141.94	74.09	98.70
Net Profit Margin	32.31	28.61	30.82
Earning Per Share	13.57	7.08	9.43
EBIDTA	198.48	111.14	146.17
Effective Tax Rate	20.93	21.02	23.22

Particulars	Mar 2025
Revenue	439.27
Operating Expense	239.46
Net Profit	141.94
Net Profit Margin	32.31
Earning Per Share	13.57
EBIDTA	198.48
Effective Tax Rate	20.93

Concord Biotech Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	1,016.94	853.17	712.93
Operating Expenses Annual	585.38	509.88	439.66
Operating Profit Annual	465.34	378.60	296.69
Interest Annual	2.55	4.51	5.48
Depreciation	51.56	49.54	45.56
Net Profit Annual	304.73	238.13	178.57
Tax Annual	104.46	81.93	62.59

Particulars	Mar 2024
Total Revenue Annual	1,016.94
Operating Expenses Annual	585.38
Operating Profit Annual	465.34
Interest Annual	2.55
Depreciation	51.56
Net Profit Annual	304.73
Tax Annual	104.46

Concord Biotech Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	3.50	0.67	5.14
Cash Flow from Operations	265.47	246	207.47
Cash Flow from Investing	-154.61	-157.95	-111.79
Cash Flow from Financing	-99.21	-85.22	-100.16
Cash Flow at the End	15.14	3.50	0.67

Particulars	Mar 2024
Cash Flow at the Beginning	3.50
Cash Flow from Operations	265.47
Cash Flow from Investing	-154.61
Cash Flow from Financing	-99.21
Cash Flow at the End	15.14

Concord Biotech Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	45.82	44.45	41.71
PBIT Margin (%)	40.55	38.12	34.69
PBT Margin (%)	27.80	30.76	29.03
Net PROFIT Margin (%)	29.97	27.91	25.05
Return On Networth / Equity (%)	21.63	19.85	16.95
Return On Networth /Employed (%)	28.81	26.05	21.86
Return On Assets (%)	21.28	18.98	15.78
Total Debt / Equity (X)	0.01	0.04	0.07
Asset Turnover Ratio (%)	0.71	0.68	0.63

Particulars	Mar 2024
PBDIT Margin (%)	45.82
PBIT Margin (%)	40.55
PBT Margin (%)	27.80
Net PROFIT Margin (%)	29.97
Return On Networth / Equity (%)	21.63
Return On Networth /Employed (%)	28.81
Return On Assets (%)	21.28
Total Debt / Equity (X)	0.01
Asset Turnover Ratio (%)	0.71

Concord Biotech Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	575.32	592.98	572.98
Total Current Assets Annual	896.23	727.70	632.67
Non Current Assets Annual	803.08	786.95	680.79
Total Shareholders Funds Annual	1,525.25	1,291.98	1,107.16
Total Assets Annual	1,699.32	1,514.65	1,313.46

Particulars	Mar 2024
Fixed Assets Annual	575.32
Total Current Assets Annual	896.23
Non Current Assets Annual	803.08
Total Shareholders Funds Annual	1,525.25
Total Assets Annual	1,699.32

Concord Biotech Ltd Earning Calls

EPS (INR)

Expected

13.42

Reported

13.42

Surprise

0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

Jun 2024

EPS beaten by 0.00%

Dividend Pages

PE Ratio

FAQS on Concord Biotech Ltd Financials

As of Jun 6, 2025, Concord Biotech Ltd has a market capitalization of 17,537.34 Cr. Value Research classifies it as a Large-Cap company.

Yes, Concord Biotech Ltd is with a debt-to-equity ratio of 0.00.

In FY 2024 , Concord Biotech Ltd recorded a total revenue of approximately 1,200.09 Cr marking a significant milestone in the company's financial performance.

Concord Biotech Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and 0.2% annually, respectively..

Concord Biotech Ltd's current PE ratio is 47.02.

Concord Biotech Ltd's ROCE averaged 26.2% from the FY ending March 2023 to 2025, with a median of 26.8%. It peaked at 27.3% in March 2025, reflecting strong capital efficiency over the period..

Concord Biotech Ltd's latest EBIT is Rs. 496.41 Cr, surpassing the average EBIT of Rs. 410.90 Cr over the 5 years..